Trogenix在4BIO Capital的支持下,开发了针对致命脑癌的新型抗癌技术。 Trogenix, backed by 4BIO Capital, develops new cancer-fighting tech targeting deadly brain cancers.

一家新公司Trogenix在4BIO Capital和几家投资者的支持下,开发了一种新技术,以针对攻击性癌症,如脑癌这一最致命的脑癌形式。 A new company, Trogenix, backed by 4BIO Capital and several investors, has developed a new technology to target aggressive cancers like glioblastoma, the most deadly form of brain cancer. 合成超增强剂技术在临床前试验中显示出有希望,具有潜在的治疗效果,没有毒性。 The Synthetic Super-Enhancer technology shows promise in preclinical trials, with potential curative effects and no toxicity. Trogenix计划在2025年开始第1/2阶段临床试验,旨在将治疗从将癌症作为一种慢性病管理转变为提供治疗选择。 Trogenix plans to begin Phase 1/2 clinical trials in 2025, aiming to shift treatment from managing cancer as a chronic disease to offering curative options.